GPCR FY2025 SEC EDGAR DEF 14A #104 of 168 in industry

Structure Therapeutics Inc. CEO pay ratio

The CEO earned $8.5M in FY2025 against median worker pay of $293,807 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
E9
Filing date
2026-04-23
Industry
Chemicals & Pharmaceuticals
Industry rank
#104/168

Data updated August 2026

Subscribe to Structure Therapeutics Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
29:1
Below Average (Scale: 0–1000:1)
CEO pay
$8.5M
Median worker
$293,807

Answer first

Structure Therapeutics Inc.'s FY2025 CEO total of $8.5M ranks #636 of 1,423 complete filings; its 29:1 pay ratio ranks #1146. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $293,807. Industry placement uses the FY2025 SIC-28 peer cohort (# 104 of 168, 39th percentile - below the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#636
$8.5M of 1,423 FY2025
Ratio rank
#1146
29:1 of 1,423
Industry pct
39th
below the industry median pay ratio

How Structure Therapeutics Inc. ranks nationally

Structure Therapeutics Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$8,520,403 Top 45% higher than 55% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). This entry sits in this band. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Structure Therapeutics Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($8.5M) against pay ratio (29:1) for Structure Therapeutics Inc. (marked) and its 4 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both03372161.56744323.010116484.613488646.127.3:131.2:135:138.9:142.7:1CEO total payPay ratio (CEO : median worker)Structure Therapeutics Inc., CEO total pay: 8520403 · Pay ratio (CEO : median worker): 29:1Structure Therapeutics Inc.Newmarket Corp, CEO total pay: 132938 · Pay ratio (CEO : median worker): 28:1Newmarket CorpProtagonist Therapeutics, Inc, CEO total pay: 12852660 · Pay ratio (CEO : median worker): 30:1Protagonist Therapeutics, IncAlkermes plc., CEO total pay: 8002710 · Pay ratio (CEO : median worker): 30:1Alkermes plc.Arcutis Biotherapeutics, Inc., CEO total pay: 7223065 · Pay ratio (CEO : median worker): 28:1Arcutis Biotherapeutics, Inc.
Structure Therapeutics Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Structure Therapeutics Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
29:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$8.5M
Companies in Industry
168
vs. Industry Median
Below
#104 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Structure Therapeutics Inc.: MODEST · HEAVY pay ratio

Structure Therapeutics Inc.'s 29:1 ratio ranks #1146 of 1,423 FY2025 complete filings (lower third by ratio). the CEO earned 29× the median employee ($293,807) in FY2025.

Median employee $293,807 (ELITE-MED); MODEST · HEAVY stamps put about 29 median-wage years per CEO year.

CEO Total Pay

$8.5M

FY2025 Summary Compensation, near median

Pay Ratio

29:1

Below typical

Structure Therapeutics Inc. in the lower-ratio third

Structure Therapeutics Inc.'s 29:1 ratio ranks #1146 of 1,423 FY2025 complete filings (lower third by ratio). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Structure Therapeutics Inc.'s $8.5M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #636 and ratio rank #1146 split - treat 29:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$8.5M
Median Employee Pay
$293,807
Pay Ratio
29:1
Filing Date
2026-04-23

Company Info

Ticker
GPCR
CIK
1888886
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
E9
View SEC filings →
SEC EDGAR DEF 14A for CIK 1888886, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Structure Therapeutics Inc.'s 29:1 ratio ranks #1146 of 1,423 FY2025 complete filings (lower third by ratio).

Read with Structure Therapeutics Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · HEAVY · ELITE-MED.

Chord Energy Corp · HEAVY

ABS(ceo_total_comp) peer at $8.5M (Δ $245 lighter vs Structure Therapeutics Inc.); MODEST · ELITE-MED vs this page's MODEST · HEAVY · ELITE-MED.
Donnelley Financial Solutions, Inc. · HEAVY

ABS(ceo_total_comp) peer at $8.5M (Δ $3K heavier vs Structure Therapeutics Inc.); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Century Communities, Inc. · HEAVY

ABS(ceo_total_comp) peer at $8.5M (Δ $5K lighter vs Structure Therapeutics Inc.); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Armstrong World Industries Inc · HEAVY

ABS(ceo_total_comp) peer at $8.5M (Δ $17K heavier vs Structure Therapeutics Inc.); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Cytokinetics Inc (SIC 28 pole)

Cytokinetics Inc stamps MODEST · UNFILED nearest in-SIC by ABS(pay_ratio) to Structure Therapeutics Inc.'s MODEST filing.
National dual ranks · #636/#1146

Structure Therapeutics Inc.'s FY2025 package sits #636 by CEO dollars and #1146 by ratio under HEAVY · MODEST.
Ratio primer · MODEST

Structure Therapeutics Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Structure Therapeutics Inc. (CIK 1888886), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.